Abiomed, Inc. (ABMD) Bundle
A Brief History of Abiomed, Inc. (ABMD)
Founding and Early Years
Abiomed was founded in 1981 by Dr. Myer Izak, focusing on developing innovative heart pump technologies. The company initially received funding of $4 million from private investors. In 1984, Abiomed launched its first product, the AbioCor, an implantable artificial heart.
Initial Public Offering and Growth
In 1993, Abiomed went public, raising approximately $35 million through its initial public offering (IPO). By 1997, the company reported revenue of around $26.4 million and has subsequently focused on expanding its product line to include devices for coronary artery disease.
Key Product Developments
Abiomed introduced the Impella heart pump in 2000, which revolutionized the treatment of coronary artery disease. The Impella device became a cornerstone of Abiomed's product offerings. By 2021, the company had sold over 100,000 Impella devices globally, generating $330 million in revenue for the fiscal year.
Recent Financial Performance
In its latest financial report for the fiscal year ended March 31, 2023, Abiomed reported total revenue of $798.6 million, marking a 23% year-over-year growth. The net income for the same period was approximately $161 million, reflecting a significant increase from prior years.
| Year | Revenue (in millions) | Net Income (in millions) | Notable Events |
|---|---|---|---|
| 2020 | $679.1 | $129.6 | Introduction of advanced Impella 5.5 |
| 2021 | $330 | $65 | Reached 100,000 Impella devices sold |
| 2022 | $648 | $138 | Expansion into international markets |
| 2023 | $798.6 | $161 | Strategic partnership with major cardiac centers |
Acquisitions and Collaborations
In 2018, Abiomed acquired HeartMate technology from St. Jude Medical, which enhanced its product offerings in the heart pump market. The acquisition cost was approximately $200 million. Collaborations with hospitals and medical centers also expanded, increasing the reach of Impella devices.
Market Position and Future Outlook
As of 2023, Abiomed holds a market capitalization of approximately $11.9 billion. The company continues to lead in the field of heart pump technology and is poised for further growth, specifically targeting the growing market for minimally invasive heart treatments.
Regulatory Approvals and Clinical Trials
Abiomed's products have received approval from the FDA, with the Impella devices undergoing several clinical trials, including the PROTECT III trial, which demonstrated significant benefits in patient outcomes. The company has invested over $100 million in clinical research and trials over the past five years.
Corporate Social Responsibility and Impact
Abiomed is committed to corporate social responsibility, supporting various health initiatives and contributing approximately $5 million annually to community health programs.
A Who Owns Abiomed, Inc. (ABMD)
Company Overview
Abiomed, Inc. (NASDAQ: ABMD) is a medical device company that focuses on heart pump technology. Founded in 1981, it is headquartered in Danvers, Massachusetts. As of 2023, the company reported revenues of approximately $253 million.
Major Shareholders
The ownership of Abiomed, Inc. is divided among various institutional and individual investors. The most significant shareholders are as follows:
| Shareholder Type | Name | Ownership Percentage | Shares Held |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 11.5% | 2,234,939 |
| Institutional Investor | Vanguard Group, Inc. | 9.8% | 1,930,500 |
| Institutional Investor | State Street Corporation | 7.2% | 1,427,300 |
| Individual Investor | Michael R. Minogue (CEO) | 1.2% | 240,000 |
| Institutional Investor | Neuberger Berman Group LLC | 5.6% | 1,110,560 |
Stock Performance
The stock performance of Abiomed has shown significant fluctuations over recent years. As of October 2023, the stock price stands at approximately $370.
Recent Acquisitions
Abiomed has made strategic acquisitions to enhance its portfolio. In October 2022, it acquired a heart pump technology company, boosting its market position.
Market Capitalization
As of October 2023, Abiomed, Inc. has a market capitalization of approximately $16 billion.
Financial Overview
Abiomed's recent financial data highlights its profitability and revenue growth:
| Year | Revenue ($ million) | Net Income ($ million) | Operating Margin (%) |
|---|---|---|---|
| 2021 | 191 | 54 | 28.3% |
| 2022 | 213 | 57 | 26.8% |
| 2023 | 253 | 60 | 23.6% |
Future Prospects
The company is expected to continue its growth trajectory with anticipated revenue of $300 million for the fiscal year 2024.
Global Reach
Abiomed products are distributed in over 70 countries worldwide, reaching a diverse patient demographic.
Abiomed, Inc. (ABMD) Mission Statement
Company Overview
Abiomed, Inc. (ABMD) is a publicly traded company focused on heart pump technologies and therapeutic devices designed to support patients with coronary artery disease and heart failure.
Mission Statement
Abiomed’s mission statement is to “recover hearts and restore lives.” This encapsulates their commitment towards developing revolutionary heart pump technology aimed at improving patient outcomes.
Core Values
- Innovation: Continuous development and enhancement of heart pump technologies.
- Quality: Commitment to exceeding regulatory standards and ensuring patient safety.
- Collaboration: Working closely with healthcare providers to optimize patient care.
- Integrity: Upholding ethical practices in all business dealings.
Financial Performance
As of the fiscal year ending March 31, 2023, Abiomed reported the following financial highlights:
| Metric | Value |
|---|---|
| Total Revenue | $426 million |
| Net Income | $65 million |
| Gross Margin | 75% |
| Operating Expenses | $150 million |
| Total Assets | $1.2 billion |
| Market Capitalization | $4.1 billion |
Recent Developments
In 2023, Abiomed received FDA approval for the new generation of the Impella heart pump, enhancing its capabilities in acute coronary syndrome treatment.
Market Position
In the global heart pump market, Abiomed holds a significant share, with an estimated market penetration of approximately 60% in the United States.
Research and Development
Abiomed invests approximately 15% of its revenue into R&D, totaling around $64 million in 2023, focusing on innovation in heart pump technology developments.
Customer Focus
The primary customers for Abiomed’s products include hospitals, cardiology clinics, and healthcare professionals specializing in heart disease treatment.
Impact Metrics
A 2023 study indicated that Impella devices have improved patient survival rates by over 70% in high-risk percutaneous coronary intervention procedures.
Community Engagement
Abiomed has committed to philanthropic efforts, contributing over $1 million annually to cardiovascular health initiatives and partnerships with medical education programs.
Future Goals
- Increase international market presence by expanding distribution in Europe and Asia.
- Launch new product lines to address heart failure and cardiogenic shock.
- Enhance customer support through advanced training programs for medical staff.
How Abiomed, Inc. (ABMD) Works
Company Overview
Abiomed, Inc. is a leading provider of heart pump technology and is headquartered in Danvers, Massachusetts. The company was founded in 1981 and specializes in developing technologies that provide circulatory support for patients with severe coronary artery diseases.
Product Portfolio
Abiomed's primary products include:
- Impella Heart Pumps: These are catheter-based heart pumps used to support patients during high-risk procedures.
- ABP (Abiomed Biventricular Pump): Designed to provide biventricular support.
| Product Type | Indications | Launch Year | 2019 Sales (in millions) | 2020 Sales (in millions) |
|---|---|---|---|---|
| Impella 2.5 | High-risk PCI | 2008 | $564 | $590 |
| Impella CP | Cardiogenic shock | 2015 | $263 | $325 |
| Impella 5.0 | Long-term support | 2016 | $128 | $162 |
Market Performance
As of the end of Q2 2023, Abiomed reported a revenue of approximately $291 million for the quarter, which represents an increase of 14% year-over-year.
Financial Performance
Key financial metrics for Abiomed include:
| Financial Metric | 2021 | 2022 | 2023 (Projected) |
|---|---|---|---|
| Revenue (in millions) | $978 | $1,098 | $1,215 |
| Net Income (in millions) | $202 | $218 | $250 |
| Gross Margin (%) | 83% | 85% | 85% |
Stock Performance
As of October 2023, the stock price of Abiomed (ABMD) was approximately $380. The company has shown a steady growth trend in the stock market with a year-to-date increase of around 20%.
Regulatory Approvals
Abiomed's products have received several regulatory approvals:
- FDA Approval: Various Impella devices have been approved for use in the U.S. market.
- CE Mark: Abiomed products are also approved for use in European markets.
Partnerships and Collaborations
Abiomed has engaged in various strategic partnerships aimed at enhancing its product offerings:
- Collaboration with Medtronic: Joint efforts to advance cardiac therapies.
- Partnership with academic institutions: Ongoing research into heart pump technologies.
Challenges and Opportunities
Abiomed faces several challenges, including competition and potential regulatory hurdles. However, the growing demand for minimally invasive heart pump solutions presents significant growth opportunities.
| Challenge | Opportunity |
|---|---|
| Increased competition from other medical device manufacturers | Expansion into emerging markets with unmet medical needs |
| Regulatory changes impacting device approvals | Technological advancements in heart pump design and functionality |
Research and Development
Abiomed invests significantly in R&D, dedicating around 12% of its annual revenue to the development of new technologies and improvement of existing products.
How Abiomed, Inc. (ABMD) Makes Money
Revenue Streams
Abiomed, Inc. generates revenue primarily through the sales of its heart pump devices, which are used in various cardiac procedures.
Product Overview
The main products include:
- Impella Heart Pumps
- Cardiogenic Shock Devices
- Heart Recovery Solutions
| Product | FY 2022 Revenues (in millions) | FY 2021 Revenues (in millions) | Growth Rate (%) |
|---|---|---|---|
| Impella 5.5 | 234 | 182 | 28.7 |
| Impella CP | 189 | 160 | 18.1 |
| Collectively | 738 | 646 | 14.2 |
Geographic Revenue Breakdown
Abiomed operates in various markets worldwide, primarily focusing on:
- United States
- Europe
- Other International Markets
| Region | FY 2022 Revenues (in millions) | FY 2021 Revenues (in millions) | Percentage of Total Revenue (%) |
|---|---|---|---|
| United States | 614 | 553 | 83.3 |
| Europe | 85 | 75 | 11.5 |
| Other International | 39 | 34 | 5.2 |
Cost Structure
The cost of goods sold (COGS) for Abiomed, Inc. includes:
- Manufacturing costs
- Research and development expenses
- Sales and marketing expenses
| Expense Type | FY 2022 Amount (in millions) | FY 2021 Amount (in millions) |
|---|---|---|
| COGS | 212 | 183 |
| R&D | 85 | 76 |
| Sales & Marketing | 123 | 112 |
Market Positioning and Competitive Advantage
Abiomed holds a prominent position in the cardiac device market due to:
- Innovative technology in heart pumps
- Strong clinical data demonstrating efficacy
- Robust training and support for healthcare providers
Recent Financial Performance
For the fiscal year 2022, Abiomed reported:
- Total revenue: $738 million
- Net income: $166 million
- Earnings per share (EPS): $4.10
| Financial Metric | FY 2022 Amount (in millions) | FY 2021 Amount (in millions) |
|---|---|---|
| Total Revenue | 738 | 646 |
| Net Income | 166 | 132 |
| Net Income Margin (%) | 22.5 | 20.4 |
Strategic Collaborations and Partnerships
Abiomed has engaged in various strategic collaborations to enhance its product offerings, including:
- Partnership with major hospitals
- Research collaborations with universities
- Joint ventures for marketing strategies
Abiomed, Inc. (ABMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support